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Interaction of CD28/CTLA-4 on T  cells with B7 on antigen-presenting cells constitutes an 
important costimulatory signal for T cells and is responsible for cyclosporin A-resistant interleukin 
2 (IL-2) gene expression and potentially also for prevention of anergy induction after T cell receptor 
triggering. In this paper, we demonstrate that addition of a monodonal antibody to BT, which 
blocks B7-CD28/CTLA-4 interaction, and of cyclosporin A  together, but not separately, to 
a primary mixed lymphocyte reaction of freshly isolated human T cells towards a human B cell 
line, induces nonresponsiveness of alloantigen-specific cytotoxic T lymphocyte precursors, whereas 
reactivity to a third party stimulator is intact. Nonresponsiveness could be reversed by culture 
in IL-2, indicating that anergy, and not clonal deletion, is responsible for this phenomenon. 
Our finding opens important perspectives for the development of new therapeutic strategies in 
transplantation. 
O 
Ptimal therapy to prevent graft rejection and GVHD 
should rely on the induction of alloantigen-specific 
anergy or elimination of donor-reactive and host-reactive T 
cells, respectively,  without the need for long-term immtmosup- 
pression. T cell anergy is currently thought to be the result 
of an intracellular signaling event after TCR/MHC-peptide 
interaction in the absence of one or more particular costimula- 
tory signals (1-4). Among the multiple costimulatory signals 
identified so far (5), the best-known candidate to determine 
whether TCR triggering leads to full T  cell activation or 
to T cell anergy, is the interaction of CD28 on the T cells 
with B7 on APC (6, 7). Costimulation through CD28 in- 
duces tyrosine phorphorylation of a number of specific sub- 
strates (8), and greatly enhances T cell activation (9-12). This 
effect involves stabilization of mRNA for several cytokines, 
including IL-2 (10). A CD28-responsive element has been 
demonstrated in the enhancer of the IL-2 gene, indicating 
that there is also regulation at the transcriptional level (13, 14). 
B7, the natural ligand for CD28 (15), is a monomeric  trans- 
membrane glycoprotein with a molecular mass of 45-65 kD 
and is, like CD28, a member of the Ig superfamily. B7 also 
binds to the CTLA-4 molecule (15), another member of the 
Ig superfam~y restricted to activated T cells. The B7 mole- 
cule is expressed on activated  B cells and activated mono- 
cytes, and constitutively on dendritic cells in both lymphoid 
and nonlymphoid tissues (16). Very recently,  the B7 mole- 
cule was shown to be involved in T cell activation in vivo. 
A soluble fusion protein of human CTLA-4 and the Ig G1 
Fc region (CTLA-4-Ig), which strongly binds to both mouse 
and human B7, was able to prevent rejection of human pan- 
creatic islets after transplantation in mice (17). CTLA-4-Ig 
could also enhance the survival of cardiac allografts  trans- 
planted into fully MHC-mismatched rats  (18). Moreover, 
blocking the B7-CD28/CTLA-4 interaction induces a specific 
hyporesponsiveness  in human T  cells after activation with 
alloantigens (19). 
Of importance with respect to transplant rejection, T cell 
coactivation mediated by CD28 has been reported to be cal- 
cium independent (20) and to be relatively resistant to inhi- 
bition with cyclosporin A (CsA)  1 (11, 12). T cell activation 
thus involves a number of CsA-sensitive mechanisms, including 
the Ca2+-associated TCR/CD3 complex-mediated intracel- 
lular signal transduction (21), besides a CsA-resistant costimu- 
latory signal from B7 (11, 12). We therefore hypothesized 
that the combination of CsA and mAb B7-24, which blocks 
B7-CD28/CTLA-4 interaction (22), would more efficiently 
block T cell activation.  In a recent study (23), we could in- 
deed demonstrate that this combination strongly inhibits 
1 Abbreviation used in this paper: CsA, cyclosporin A. 
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present study, we questioned whether the presence of CsA 
and a mAb against the B7 molecule during a primary MLR 
between freshly isolated human T cells and a B7-expressing 
EBV-transformed human B cell line as stimulator, could in- 
duce nonresponsiveness or anergy of human CTL precursors. 
T cell nonresponsiveness was studied at the cytotoxic effector 
level, which was selected as being most relevant  for trans- 
plant rejection and most dif~cult to induce (24,  25).  Our 
findings may be of considerable importance for the develop- 
ment of new therapeutic strategies  aimed at prevention of 
transplant rejection and treatment of CsA- and corticosteroid- 
resistant GVHD. 
Materials and Methods 
Cells and Cell Lines.  Peripheral  blood T cells were isolated  from 
healthy volunteers as described (12). The resulting population is 
devoid  orB ceils, NK cells, and monocytes. The cells  were cultured 
in RPMI 1640 (Gibco, Paisley,  Scotland)  supplemented  with 2 mM 
t-glutamine, penicillin  (100 U/nil), streptomycin  (100/~g/ml), and 
10% iron-supplemented  bovine  calf  serum (complete medium). Two 
EBV-transformed B cell lines were used as stimulator cells for the 
MLK: ARC, obtained from the American Type Culture Collec- 
tion (ATCC [Rockville, MD]) (HLA-DR w8,wS), and MM, pro- 
duced at Innogenetics (HLA-DR 1,2). The P815 cell line (ATCC) 
is a DBA/2-derived  NK-resistant mouse mastocytoma  cell line that 
expresses Fcq,  RII and Fc3,RIII. 
Monoclonal Antibodies and Other  Reagents.  mAb B7-24 (IgG2a, 
K) was obtained from a fusion with splenocytes  from a mouse im- 
munized with SD insect cells expressing the human B7 molecule 
(22, 26) and was used as purified Ab. Anti-CD3  mAb OKT3 
(IgG2a, K) was used as purified Ab isolated from the supematant 
of  the OKT3 done obtained from the ATCC. CsA (purchased  from 
Sandoz Pharmaceuticals,  Basal, Switzerland)  was dissolved  in RPMI 
1640 (stored at 4~  rlL-2, produced by Hoffmann-La Roche 
(Nutley, NJ),  was  obtained  through the  Biological Response 
Modified Program (National Cancer Institute, Frederick, MD). A 
second rlL-2 preparation was purchased from Boehringer-Mannheim 
(Mannheim, Germany). rib4 was produced at Innogenetics. 
Mixed Lymphocyte Reactions.  For the primary MLK, 106 T cells 
were cultured with 0.25  x  106 ARC cells (irradiated with 2,000 
tad), for 5-7 d in 24-well flat-bottom tissue culture plates in I ml 
of medium, mAb B7-24 and/or CsA were added from the begin- 
ning of the culture period. After 5-7 d, the cells were harvested 
and resuspended  in medium for direct analysis  of  cytotoxic capacity 
or for restimulation in a secondary MLR. In the latter case, the 
cells were first rested in medium alone during 1-2 d in the absence 
of the stimulator calls. The T cells were then restimulated in a 
secondary MLR with irradiated ARC cells or MM cells at a T 
cellAtimulator cell ratio of 4:1 without CsA or anti-B7. 4 d later, 
the cells were harvested and resuspended in medium for analysis 
of cytotoxic capacity or for further culture. If a tertiary MLR was 
performed, the cells were again restimulated with ARC cells or 
MM cells (T cellAtimulator ceil ratio, 4:1) for 4-5 d without CsA 
or anti-B7, and then tested for their cytotoxic capacity. Ib2 in the 
culture  supernatants was assayed with a bioassay as previously 
reported (27). 
Cytotoxicity Assay.  Cytotoxic activity was measured in a 4-h 
target cell  lysis  assay  using murine P815 ceils  or ARC cells as targets. 
In  the  case of the  P815 target  cells, the  CTL were bridged 
nonspecifically  to the target cells using the anti-CD3 mAb OKT3 
at 2/~g/ml (12). This anti-CD3-redirected cytotoxicity assay thus 
evaluates all  T  cell cytotoxic activity, irrespective of antigen 
specificity. When the ARC cells were used as target cells, only 
the alloantigen-specific  CTL supposedly  participated in the killing 
process. One million target cells were labeled with 200/zCi of 
[SlCr]sodium chromate  (Amersham International,  Amersham, 
Bucks, UK). The CTL assays  were performed in 96-well V-bottom 
microtiter plates using 5,000 SlCr-labeled target cells with 5  x 
104 T cells (E/T ratio =  10, unless otherwise indicated) in a total 
volume of 200/zl/well. Four wells were filled with 5 x  103 target 
cells in 200/~1 medium alone, and four wells with 5 x  103 target 
cells in 100 #1 medium and 100/~1 saponin for evaluation  of sponta- 
neous and maximal release, respectively. The percentage of anti- 
CD3-dependent  SlCr release of P815 cells was calculated as de- 
scribed (12). Percent lysis of ARC cells was calculated as follows: 
100 x  [(total release by the T cells -  spontaneous release)/(max- 
imal release by saponin -  spontaneous release)]. 
Results and Discussion 
We analyzed the effect of CsA and of  blocking B7-CD28/ 
CTLA-4 interaction with mAb B7-24 during a primary MLR 
of freshly isolated human T  cells against EBV-transformed 
human B cell lines (ARC or MM) on subsequent restimula- 
tion with the same or different stimulator cells. Alloantigen- 
specific and total anti-CD3-redirected cytotoxic activity  were 
measured as a read-out system for CTL activation. T  cells 
primed with ARC displayed cytotoxic activity after a pri- 
mary, and more so, after a secondary MLR (Fig. 1). As also 
demonstrated in Fig. 1, the combination of B7-24 mAb and 
CsA, but not each of them separately, blocked the genera- 
tion of CTL during the primary MLR, and, more impor- 
tantly, prevented subsequent CTL generation in a secondary 
MLR performed with the same stimulator cells but in the 
absence  of these blocking agents.  In other words, T  cells 
primed in an MLR in the presence of  both anti-B7 and CsA, 
are nonresponsive upon restimulation with the same alloan- 
tigen. Tan et al.  (19) demonstrated that CTLA-4-Ig alone 
induces alloantigen-specific  hyporesponsiveness  in human T 
cell cultures as measured by proliferation. In our experiments 
using a CTL evaluation for induction of nonresponsiveness, 
the mAb B7-24 alone did not consistently enter the cells in 
a nonresponsive state, although we also sometimes found a 
state of hyporesponsiveness  after a primary MLR with anti- 
B7 alone (data not shown). However, the combination of 
CsA and mAb B7-24 added during the primary MLR con- 
sistently prevented alloantigen-induced CTL generation in 
a secondary MLR (Fig. 2). Varying the CsA concentration 
from 200 to 1,600 ng/ml or the anti-B7 concentration from 
0.1 to 10/~g/ml resulted in an identical state of nonrespon- 
siveness (data not shown). Also, after a second restimulation 
with ARC (tertiary MLR), the cells made nonresponsive 
during the primary MLR with CsA and mAb B7-24  dis- 
played no cytotoxic activity (Fig.  2),  indicating the persis- 
tence of nonresponsiveness.  CsA with anti-CD58 (LFA-3) 
mAb or with anti-CD54 (intercellular adhesion molecule 1 
[ICAM-1]) mAb could not induce this state of nonrespon- 
siveness (data not shown). 
To exclude cell death as a cause of nonresponsiveness  in 
the secondary MLR, T cells were first rendered nonrespon- 
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Figure  1.  Synergy  between 
mAb B7-24 and CsA in blocking 
the primary MLR and in inducing 
persistent  alloantigen  nonrespon- 
siveness of CTL precursors. Purified 
human T cells were stimulated with 
irradiated  ARC cells in a 7-d pri- 
mary MLR. CsA (400 ng/ml) and/ 
or  mAb  B7-24  (10  /~g/ml)  was 
added during the primary MLK as 
indicated.  T cells were then rested 
for 2 d and restimulated with ARC 
cells in a 4-d secondary MLK, in the 
absence of CsA or anti-B7. CTL ac- 
tivity after primary and after sec- 
ondary  MLIL was measured  in an 
anti-CD3-redirected  cytotoxicity 
assay against P815 mastocytoma cells 
(top) and in an alloantigen-specific 
cytotoxicity assay against the origi- 
nal stimulator cells (bottom)  and is 
expressed  as  percent  lysis of the 
target cells. Results of one represen- 
tative experiment  out of 10. 
sive to ARC as before, and were then restimulated polyclonaUy 
with immobilized anti-CD3 and IL-2. Anti-CD3-redirected 
cytotoxicity  was used as a read-out system for polyclonal CTL 
generation. As can be seen in Fig. 3 a, when the cells were 
cultured in the primary MLR with ARC, CsA, and anti- 
B7, th~ could still be stimulated polyclonally to the same 
extent as the control cells primed with ARC alone.  Induc- 
tion of nonresponsiveness could be the result of either anergy, 
or of clonal deletion. In the first case, it should be possible 
to overcome the anergic state with IL-2 (2, 6), whereas IL-2 
would have no effect after clonal deletion. T cells that were 
either primed with ARC or rendered nonresponsive to ARC, 
were restimulated with ARC or with IL-2. It is shown in 
Fig. 3 b that T cells cultured in the primary MLR with ARC, 
CsA, and anti-B7 could not be restimulated with ARC. How- 
ever, after culture in IL-2, these cells displayed again a strong 
cytotoxic activity towards ARC. It can be concluded that 
nonresponsiveness in this in vitro model is due to anergy in- 
duction. 
To study the alloantigen specificity of the anergy induc- 
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Figure  2.  The  combination  of 
CsA and anti-B7 during a primary 
MLR induces persistent alloantigen 
nonresponsiveness upon restimula- 
tion in secondary and tertiary MLR. 
T  cells were stimulated  during  a 
primary MLR, using ARC as sti- 
mulator  cells,  without  or  with 
mAb B7-24  (10/~g/ml) and  CsA 
(400 ng/ml) and were then restimu- 
lated with ARC alone. Addition of 
anti-B7  and  CsA to  the primary 
MLR significantly reduced the cyto- 
toxic activity after secondary MLR 
(n  =  10, top)  or tertiary MLR (n 
=  3,  bottom),  measured  with the 
anti-CD3-redirected  cytotoxic assay 
against P815 (left, Student's t test of 
paired samples: p <0.0001) or with 
an antigen-specific cytotoxic assay 
against the original ARC stimulator 
cells (right,  Student's t test of paired 
samples: p <0.005).  (A) T cells cul- 
tured in the primary MLR with 
ARC; (B) T cells cultured in the pri- 
mary MLR with ARC,  anti-B7, 
and CsA. 
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Figure  3.  Restimulation with immobilized anti-CD3 (A) or with IL-2 
(B) can reverse anergy. (A) T cells were first stimulated during 7 d with 
irradiated ARC cells without or with CsA (400 ng/ml) and mAb B7-24 
(10/~g/ml). Thereafter, the cells were restimulated with ARC cells or with 
immobilized anti-CD3 (UCHT'I)  + IL-2 (10 U/ml,  Boehringer Mann- 
heim) for 4 d. Immobilization of UCHT1 was done by preincubation of 
the culture plates with purified UCHT1 (5/zg/ml) for 4 h at 37~  (12). 
CTL activity  was measured  in an anti-CD3-redirected  cytotoxic  assay  against 
P815 mastocytoma  cells (E/T  =  20). The data are representative of two 
experiments. (B) T cells were primed with irradiated ARC or rendered 
tion, ARC-primed and nonresponsive T  cells were restimu- 
lated once or twice with ARC cells (HLA-DR w8,w8) or 
third  party MM  (HLA-DR  1,2) cells.  The T  cells  treated 
with CsA and B7-24 mAb in a primary MLR towards ARC, 
displayed cytotoxic activity when restimulated with MM cells, 
indicating that only the ARC-specific T cells were nonrespon- 
sive (Table  1). 
The anergy induction obtained by alloantigen stimulation 
in the presence of mAb B7-24 and CsA has to be considered 
as an active process for several  reasons. First,  a minimum of 
5 d culture with stimulator cells, followed by 1 or 2 d culture 
in medium alone, were needed to yield an anergic state (data 
not shown). Moreover, the activation marker HLA-DR was 
expressed  on a proportion of the cells  stimulated  with  al- 
loantigen in the presence of mAb B7-24 and CsA (24 and 
33% HLA-DR positive cells in two experiments), compared 
to 2  and 4%  in  the  starting population,  and  51  and  31% 
after stimulation with alloantigen alone. The cells cultured 
with  mAb B7-24 and  CsA during  alloantigen  stimulation 
did,  however,  not express CD25  (IL-2 receptors)  (data not 
shown). 
IL-2 has been shown to prevent the anergic state of T cells, 
anergized by antigen stimulation in the absence of costimula- 
tory signals (19). Fig. 4 demonstrates that alloantigen-specific 
anergy induction in human T  cells by CsA and mAb B7-24 
could also be prevented by adding IL-2 during the primary 
MLR.  This IL-2 effect could be blocked by a combination 
of mAb anti-Tac and mik/31 against the p55 and p70 chain 
of the IL-2 receptor (data not shown).  These data  suggest 
the importance of the IL-2 production defect for induction 
nonresponsive against ARC during a primary MLR with the combina- 
tion of CsA (400 ng/ml) and mAb B7-24 (10 #g/ml).  Thereafter, cells 
were restimulated with ARC cells or IL-2  (10 U/ml). Antigen-specific  CTL 
activity was measured after 4 d (E/T  =  20). The data are representative 
of three experiments. No LAK activity against ARC was found in control 
experiments with unprimed T cells cultured in I1.-2 (10 U/ml)  alone. 
Table 1.  Altoantigen  Specificity of Nonresponsiveness Demonstrated by Restimulation  with the Priming Cells or Third Party Stimulator Cells 
Stimulator cells 
Secondary MLR*  Tertiary MLR* 
Percent  lysis of P815  cells* by 
ARC primed cellr  ARC nonresponsive cellr 
ARC  -  40  6 
MM  -  ND  38 
ARC  ARC  83  8 
MM  ARC  ND  53 
ARC  MM  84  16 
MM  MM  ND  54 
* After the secondary or tertiary MLR, the cells were harvested and an anti-CD3-redirected cytotoxic assay was performed with an effector/target 
ratio of 10:1 against anti-CD3-coated P815. 
After the primary MLR with ARC stimulator cells, and after a 1-d period of culture in medium alone, the cells were restimulated with ARC 
or with MM (T cell/stimulator cell ratio, 4:1). After 5 d of secondary MLR,  the remaining cells were harvested and cultured in medium alone 
for 1 d. A tertiary MLR was performed with ARC or MM as indicated (T cell/stimulator cell ratio, 4:1). 
S Alloantigen-primed or nonresponsive cells were generated in a 5-d primary MLR,  depending on whether T cells were stimulated with ARC in 
the absence (primed cells) or presence (nonresponsive cells) of anti-B7 (10/xg/ml)  and CsA (400 ng/ml). 
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Figure 4.  IL2 prevents the induction of anergy with mAb B7-24 and 
CsA in a primary MLR. Purified human T cells were stimulated with 
irradiated ARC cells in a primary MLR (5 d) without or with CsA (400 
ng/ml) and mAb B7-24 (10/~g/ml). II_,2 (10 U/ml, Hoffmann-La  Roche) 
or IL-4 (200 U/ml) were added during the primary MLR as indicated. 
After the secondary  MLR (4 d), CTL activity was measured in an anti- 
CD3-redirected cytotoxic assay against P815 mastocytoma cells. 
of the anergic state.  In contrast, adding IL-4 to the primary 
MLR in the presence of mAb B7-24 and CsA had no effect 
(Fig.  4). 
We subsequently measured IL-2 production in a primary 
MLR with a bioassay as described (27). IL-2 production in 
the presence of mAb B7-24 decreased to 28% of the control 
MLR (being 75 U/ml). CsA alone lowered the IL-2 produc- 
tion to 21% of the control level. However, using both CsA 
and mAb B7-24, the residual IL-2 production was only 2% 
of the control level. Thus, anti-B7 and CsA together almost 
completely block IL-2 production in the primary MLR, and 
this might be responsible for anergy induction,  as the latter 
could be prevented by addition of IL-2 during the induction 
phase. The failure of anti-B7 alone to induce anergy can most 
likely be explained by a persistent IL-2 production, induced 
by TCR triggering in combination with signaling from other 
accessory molecules such as LFA-3 or ICAM-1 on APC (5). 
These additional costimulatory signals could then probably 
be blocked by CsA. CsA can prevent T  cell activation only 
when the activation is dependent on elevations in cytosolic 
Ca  2+  (21).  The  CD2-LFA-3  ligation  induces  a phospho- 
lipase-C3,1 tyrosine phosphoryhtion, regulates CD3 signaling, 
and induces an increased concentration  of free cytoplasmic 
Ca  2  + (28). It has been demonstrated that this CD2-mediated 
pathway of activation is highly CsA sensitive (29). Although 
the mechanism ofcostimulation through LFA-1 remains un- 
clear, evidence for signaling through LFA-1 comes from studies 
in which crosslinking ofT cell LFA-1 with mAbs was found 
to induce increased intracellular  Ca  2+  concentrations  (30), 
which may also suggest a CsA-sensitive intraceUular signal 
transduction.  The  B7-CD28/CTLA-4  interaction  indeed 
seems to be the only signal that confers CsA-resistant IL-2 
production  (11, 12). 
Our findings that CsA contributes to the induction of a 
state of anergy, are in apparent contradiction with earlier work 
by Jenkins et al. (1-3) who found that CsA blocked the in- 
duction of nonresponsiveness in mouse T cell clones stimu- 
lated with antigen and chemically modified APC, and sug- 
gested that  a calcium  signal,  mediated via the TCR,  was 
essential for induction of anergy. Several differences between 
the model of Jenkins and our model are obvious. We used 
freshly isolated human T cells and anergy was studied at the 
cytotoxic effector level.  Fresh virgin T  cells versus memory 
cells (T cell clones) might have totally different requirements 
for anergy induction,  and anergy induction models have al- 
ready been  shown to differentially affect IL-2 versus IL-4 
production (19) or proliferation  versus CTL induction (24, 25). 
The mechanism of how blocking of TCR signal transduc- 
tion by CsA can contribute to anergy induction remains an 
intriguing  problem.  It cannot be excluded that  a calcium- 
independent limb of the TCR signaling pathway, unaffected 
by CsA, is required for induction of anergy. As CsA affects 
late steps of intracellular signal transduction, changes in early 
signaling events after TCtL triggering might be responsible 
for hyporesponsiveness after TCR triggering in the presence 
of anti-B7 and CsA. Alterations in tyrosine phosphorylation 
signaling events with reduced amounts of the protein tyro- 
sine kinase p56  kk and constitutively elevated levels of the pro- 
tein tyrosine kinase p56~ have already been described using 
a model of anergy induction with immobilized anti-CD3 mAb 
(31).  Further  studies are required  to address these issues. 
In conclusion,  CTL precursors  in vitro become anergic 
when signals derived both from CsA-resistant  B7-CD28/ 
CTLA-4  interaction  and from CsA-sensitive pathways are 
blocked during alloantigen stimulation.  This approach may 
have major implications for organ and bone marrow trans- 
plantations: prevention of graft rejection and of GVHD. How- 
ever,  further studies in animal models are required to sub- 
stantiate this approach before trials in humans can be started. 
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